Amplified Sciences to Present Abstract at ASCO

WEST LAFAYETTE, Ind. (June 2, 2022) – Amplified Sciences, Inc., a privately held startup developing diagnostic solutions for accurate, earlier detection of devasting disease, announced Thursday (June 2) they will make a poster presentation at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 3-7.

Daniel A. Sheik, Ph.D., Director of Research and Technology Development, will present findings from clinical testing data of their lead assay for early detection and diagnosis of pancreatic cancer in patients with cystic lesions.

“This data provides substantial support for Amplified Sciences’ platform and provides a potential solution in the field of pancreatic cancer,” shared CEO Diana Caldwell. “By providing a highly accurate diagnostic test utilizing a small volume of fluid, it may be possible to provide more insights to clinicians who are managing patients with concerning pancreatic cystic lesions.”

Amplified Sciences’ schedule of presentation is as follows:

• Discrimination of mucinous pancreatic cysts using an enzymatic turnover assay to improve clinical diagnostic accuracy

Abstract # 4151, Saturday, June 4, 8-11 a.m. at McCormick Place Convention Center, Hall A, Chicago, in the Gastrointestinal Cancer Session — Gastroesophageal, Pancreatic, and Hepatobiliary  

—

ABOUT AMPLIFIED SCIENCES

Amplified Sciences is a startup life science diagnostics company focused on detecting and pre-empting the risks of debilitating diseases, thus providing health providers the ability to treat patients earlier with better outcomes. The company has operations in West Lafayette, Indiana, leverages technology licensed from Purdue University, and has developed a diagnostic platform that scales to point of care. To learn more about Amplified Sciences, visit amplifiedsciences.com.